BMRN · NASDAQ
BioMarin Pharmaceutical (BMRN) Stock Price & Fundamentals
BioMarin Pharmaceutical (BMRN) closed at $480.92 on Oct 9, 2026, down 0.04% from the previous close of $481.11.
Share price, past year
1Y +59.93%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $480.92 |
| Sep 30, 2026 | $483.07 |
| Aug 31, 2026 | $501.48 |
| Jul 31, 2026 | $478.53 |
| Jun 30, 2026 | $481.77 |
| May 29, 2026 | $437.50 |
| Apr 30, 2026 | $427.93 |
| Mar 31, 2026 | $422.59 |
| Feb 27, 2026 | $418.89 |
| Jan 30, 2026 | $401.00 |
| Dec 31, 2025 | $366.76 |
| Nov 28, 2025 | $330.35 |
| Oct 31, 2025 | $315.81 |
Key statistics
- Market cap
- $93.08B
- P/E (TTM)
- 1,233.1
- EPS (TTM)
- $0.39
- Revenue (TTM)
- $3.41B
- Net income (TTM)
- $72.97M
- Shares outstanding
- 193.5M
- Dividend yield
- —
- 52-week range
- $299.77 – $503.27
BioMarin Pharmaceutical's market cap is $93.08B, based on a share price of $480.92 and 193.5M shares outstanding as of Jun 30, 2026.
Financials
BioMarin Pharmaceutical reported revenue of $3.22B for fiscal 2025, up 12.87% from fiscal 2024.
BioMarin Pharmaceutical earned net income of $348.90M in fiscal 2025, a net margin of 10.8%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $3.22B | +12.9% | $348.90M | 10.8% | $1.80 | $724.96M |
| FY2024ended Dec 31, 2024 | $2.85B | +18.0% | $426.86M | 15.0% | $2.21 | $487.42M |
| FY2023ended Dec 31, 2023 | $2.42B | +15.4% | $167.65M | 6.9% | $0.87 | $62.57M |
| FY2022ended Dec 31, 2022 | $2.10B | +13.5% | $141.56M | 6.8% | $0.75 | $54.94M |
| FY2021ended Dec 31, 2021 | $1.85B | −0.8% | −$64.08M | −3.5% | −$0.35 | $208.96M |
| FY2020ended Dec 31, 2020 | $1.86B | +9.2% | $854.03M | 45.9% | $4.50 | −$28.95M |
| FY2019ended Dec 31, 2019 | $1.70B | +14.3% | −$23.85M | −1.4% | −$0.13 | −$96.76M |
| FY2018ended Dec 31, 2018 | $1.49B | +13.5% | −$77.21M | −5.2% | −$0.44 | −$124.41M |
| FY2017ended Dec 31, 2017 | $1.31B | +17.6% | −$117.04M | −8.9% | −$0.67 | −$207.98M |
| FY2016ended Dec 31, 2016 | $1.12B | — | −$630.21M | −56.4% | −$3.81 | −$376.22M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $989.71M | $44.76M | $0.23 |
| Q1 FY2026ended Mar 31, 2026 | $766.21M | $105.53M | $0.54 |
| Q4 FY2025ended Dec 31, 2025 | $874.57M | −$46.57M | −$0.22 |
| Q3 FY2025ended Sep 30, 2025 | $776.13M | −$30.74M | −$0.16 |
| Q2 FY2025ended Jun 30, 2025 | $825.41M | $240.53M | $1.23 |
| Q1 FY2025ended Mar 31, 2025 | $745.15M | $185.69M | $0.95 |
| Q4 FY2024ended Dec 31, 2024 | $747.31M | $124.94M | $0.65 |
| Q3 FY2024ended Sep 30, 2024 | $745.74M | $106.08M | $0.55 |
Company profile
- Name
- BioMarin Pharmaceutical Inc.
- Ticker
- BMRN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 105 Digital Drive, Novato, CA 94949
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001048477
Recent SEC filings
- Oct 6, 2026
- Sep 30, 2026
- Sep 15, 2026
- Sep 14, 2026
- Sep 1, 2026
- Aug 31, 2026
- Aug 18, 2026
- Aug 6, 2026
Frequently asked questions
What is BioMarin Pharmaceutical's stock price?
BioMarin Pharmaceutical (BMRN) closed at $480.92 on Oct 9, 2026, down 0.04% from the previous close of $481.11.
What is BioMarin Pharmaceutical's market cap?
BioMarin Pharmaceutical's market cap is $93.08B, based on a share price of $480.92 and 193.5M shares outstanding as of Jun 30, 2026.
How much revenue does BioMarin Pharmaceutical make?
BioMarin Pharmaceutical reported revenue of $3.22B for fiscal 2025, up 12.87% from fiscal 2024.
What is BMRN's P/E ratio?
BioMarin Pharmaceutical's price-to-earnings ratio is 1,233.1, based on trailing twelve-month diluted EPS of $0.39.
Does BioMarin Pharmaceutical pay a dividend?
BioMarin Pharmaceutical's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from BioMarin Pharmaceutical Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures